This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration

Sponsored by Perceive Biotherapeutics, Inc.

About this trial

Last updated 2 years ago

Study ID

PBI-AMD-002

Status

Recruiting

Type

Interventional

Phase

Phase 1/Phase 2

Placebo

No

Accepting

18-75 Years
50+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 2 years ago

What is this trial about?

The Phase 1 safety study of VOY-101 comprises a two dose Cohort escalation, followed by a Phase 2a.

What are the participation requirements?

Yes

Inclusion Criteria

- Are ≥50 years of age at the time of consent.

- Are willing and able to understand and provide written informed consent.

- Are willing and able to return for scheduled treatment and follow-up examinations.

- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.

- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.

- Absence of signs of non-exudative MNV.

- Additional Ocular Inclusion Criteria for study eye.

- Meet certain genotype criteria for risk of AMD.

No

Exclusion Criteria

- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.

- Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Locations

Location

Status

Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting